{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"102"},{"groupId":"OG001","value":"51"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"105"},{"groupId":"OG001","value":"54"}],"units":"Participants"}],"description":"An AE is defined as any unfavorable and unintended sign, symptom, or disease (new or worsening) temporally associated with the use of study therapy, regardless of whether or not a causal relationship with the study therapy. The number of participants who experienced an AE is presented.","groups":[{"description":"Participants received pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for up to 35 doses (approximately 24 months).","id":"OG000","title":"Recurrent or Metastatic Cutaneous cSCC Cohort"},{"description":"Participants received pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for up to 35 doses (approximately 24 months).","id":"OG001","title":"Locally Advanced Unresectable cSCC Cohort"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The analysis population consisted of all participants who received ≥1 dose of study treatment.","reportingStatus":"POSTED","timeFrame":"Up to approximately 56 months","title":"Number of Participants Who Experienced One or More Adverse Events (AEs)","type":"SECONDARY","unitOfMeasure":"Participants"}